Legal Opinion

Boehringer Ingelheim Pharmace v. David R. Herndon

Court of Appeals for the Seventh Circuit

Decided January 24, 2014No. 13-3898PublishedCited by 13 opinions

1Opinion of the Court

POSNER, Circuit Judge.

Pradaxa is a prescription blood-thinning drug manufactured by an American company and its German affiliate (collectively Boehringer). A number of suits against Boehringer complaining about the accuracy of the warning label on the drug have been consolidated in the Southern District of Illinois for pretrial proceedings. The litigation is in the discovery stage. On December 9 of the just-ended year, the district judge presiding over the litigation imposed sanctions on Boehringer for discovery abuse. Boehringer has petitioned us for a writ of mandamus quashing the sanctions.

2Cases cited5 opinions

  1. Cheney v. United States District Court for District of ColumbiaSupreme Court of the United States · 2004
  2. Mohawk Industries, Inc. v. CarpenterSupreme Court of the United States · 2009
  3. Chaunte Ott v. City of MilwaukeeCourt of Appeals for the Seventh Circuit · 2012
  4. United States v. Christopher P. DrogoulCourt of Appeals for the Eleventh Circuit · 1993
  5. RELATIONAL, LLC v. HodgesCourt of Appeals for the Seventh Circuit · 2010

3Cited by13 opinions

  1. in Re Sun Coast Resources, Inc., Texas Court of Appeals, 14th District (Houston)2018
  2. Knight v. Boehringer Ingelheim Pharm., Inc.United States District Court · 2018
  3. Elliot v. Mission Trust Services, LLCDistrict Court, N.D. Illinois · 2015
  4. United States v. Paul Davis, Jr.Court of Appeals for the Seventh Circuit · 2014
  5. Covarrubias v. Wendy's Properties, LLCDistrict Court, N.D. Illinois · 2021

8 more not listed; retrieve them via the Exa API.

Showing a preview — retrieve the full document via the Exa API.

Powered by the Exa API